24 results on '"Yin, Yongmei"'
Search Results
2. Heat-shock protein 90α protects NME1 against degradation and suppresses metastasis of breast cancer.
- Author
-
Zhang, Yanchao, Zhao, Guomeng, Yu, Liting, Wang, Xindong, Meng, Yao, Mao, Jinlei, Fu, Ziyi, Yin, Yongmei, Li, Jinyao, Wang, Xun, and Guo, Changying
- Abstract
Background: NME1 has been exploited as a potential translational target for decades. Substantial efforts have been made to upregulate the expression of NME1 and restore its anti-metastasis function in metastatic cancer. Methods: Cycloheximide (CHX) chase assay was used to measure the steady-state protein stability of NME1 and HSP90α. The NME1-associating proteins were identified by immunoprecipitation combined with mass spectrometric analysis. Gene knockdown and overexpression were employed to examine the impact of HSP90AA1 on intracellular NME1 degradation. The motility and invasiveness of breast cancer cells were examined in vitro using wound healing and transwell invasion assays. The orthotopic spontaneous metastasis and intra-venous experimental metastasis assays were used to test the formation of metastasis in vivo, respectively. Results: HSP90α interacts with NME1 and increases NME1 lifetime by impeding its ubiquitin-proteasome-mediated degradation. HSP90α overexpression significantly inhibits the metastatic potential of breast cancer cells in vitro and in vivo. A novel cell-permeable peptide, OPT22 successfully mimics the HSP90α function and prolongs the life span of endogenous NME1, resulting in reduced metastasis of breast cancer. Conclusion: These results not only reveal a new mechanism of NME1 degradation but also pave the way for the development of new and effective approaches to metastatic cancer therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study.
- Author
-
Xu, Binghe, Sun, Tao, Shi, Yanxia, Cui, Jiuwei, Yin, Yongmei, Ouyang, Quchang, Liu, Qiang, Zhang, Qingyuan, Chen, Yiding, Wang, Shouman, Wang, Xiaojia, Tong, Zhongsheng, Zhong, Yahua, Wang, Jiayu, Yan, Min, Yan, Xi, Wang, Chuan, Feng, Jifeng, Wang, Xiuli, and Hu, Gang
- Abstract
Purpose: To evaluate the efficacy and safety of pamiparib in patients with locally advanced or metastatic human epidermal growth factor receptor 2-negative (HER2−) breast cancer, with deleterious or suspected deleterious germline BRCA1/2 mutations (gBRCA1/2 m). Methods: In this open-label, phase II, multicenter study in China (NCT03575065), patients with triple-negative breast cancer (TNBC cohort) or hormone receptor-positive (HR+)/HER2− breast cancer (HR+/HER2− cohort) and ≤ 2 prior lines of chemotherapy received pamiparib 60 mg orally twice daily in 28-day, continuous cycles. The primary endpoint was objective response rate (ORR; RECIST v1.1) by independent review committee. Results: In total, 88 patients were enrolled (TNBC cohort: 62; HR+/HER2− cohort: 26). Median age was 45.5 (range: 27–67) years, and 60 patients (68.2%) had received 1 or 2 prior lines of chemotherapy; 42 patients (47.7%) had previously received platinum chemotherapy. In the TNBC cohort, ORR was 38.2% (95% confidence interval [CI] 25.4–52.3) and median duration of response (DoR) was 7.0 months (95% CI 3.9–not estimable). In the HR+/HER2− cohort, ORR was 61.9% (95% CI 38.4–81.9) and median DoR was 7.5 months (95% CI 5.6–14.8). The most common treatment-emergent adverse events (TEAEs), treatment-related TEAEs, and ≥ Grade 3 TEAEs were hematologic (including anemia, decreased neutrophil count, and decreased white blood cell count). Overall, 64.8% of patients had TEAEs leading to dose reduction and 2.3% had TEAEs leading to treatment discontinuation. Conclusion: Pamiparib showed encouraging efficacy and an acceptable safety profile in patients with locally advanced and metastatic HER2− breast cancer with gBRCA1/2 m. Trial registration: ClinicalTrials.gov, NCT03575065; July 2, 2018. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study.
- Author
-
Xu, Binghe, Li, Wei, Zhang, Qingyuan, Li, Qiao, Wang, Xiaojia, Li, Huiping, Sun, Tao, Yin, Yongmei, Zheng, Hong, Feng, Jifeng, Zhu, Huaqi, Siddiqui, Asna, Macharia, Harrison, and Knott, Adam
- Abstract
Purpose: PUFFIN (NCT02896855), a Chinese bridging study in patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer, assessed consistency of efficacy and safety of pertuzumab plus trastuzumab and docetaxel versus placebo, trastuzumab, and docetaxel, with CLEOPATRA (NCT00567190). Methods: Eligible patients, n = 243, were randomized 1:1, stratified by visceral disease and hormone receptor status, to pertuzumab, trastuzumab, and docetaxel or placebo, trastuzumab, and docetaxel. Primary endpoint: investigator-assessed progression-free survival (PFS). Secondary endpoints: safety and overall survival (OS). After primary analysis, patients could cross over to the pertuzumab arm. Results: Updated median PFS: 16.5 months (pertuzumab arm) and 12.5 months (placebo arm), with a hazard ratio (HR) of 0.60 [95% confidence interval (CI) 0.45, 0.81; p = 0.0008]. Median OS was not reached in either arm; the OS HR was 0.68 (95% CI 0.45, 1.03; p = 0.0658). Safety was similar in both arms with no new safety signals: 73.8% (pertuzumab arm) and 69.2% (placebo arm) experienced grade ≥ 3 adverse events. No heart failure, symptomatic left ventricular systolic dysfunction, or left ventricular ejection fraction decline of < 40% were reported. Conclusions: The PUFFIN final analysis showed, per the primary analysis, that overall efficacy of pertuzumab plus trastuzumab and docetaxel was consistent with CLEOPATRA. Safety remained consistent with the known pertuzumab profile. Overall, PUFFIN contributes to the totality of data with pertuzumab in previously untreated HER2-positive locally recurrent or metastatic breast cancer and supports the favorable benefit–risk profile of pertuzumab in Chinese patients. Trial registration: ClinicalTrials.gov, NCT02896855, registered 7 September 2016. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. A positive feedback loop: RAD18-YAP-TGF-β between triple-negative breast cancer and macrophages regulates cancer stemness and progression.
- Author
-
Yan, Xueqi, He, Yaozhou, Yang, Shikun, Zeng, Tianyu, Hua, Yijia, Bao, Shengnan, Yang, Fan, Duan, Ningjun, Sun, Chunxiao, Liang, Yan, Fu, Ziyi, Huang, Xiang, Li, Wei, and Yin, Yongmei
- Published
- 2022
- Full Text
- View/download PDF
6. JWA suppresses proliferation in trastuzumab-resistant breast cancer by downregulating CDK12.
- Author
-
Liang, Yan, Qian, Chao, Xie, Yinghong, Huang, Xiang, Chen, Junjie, Ren, Yanlin, Fu, Ziyi, Li, Yongfei, Zeng, Tianyu, Yang, Fan, Zhou, Jianwei, Li, Wei, Yin, Yongmei, and Wang, Changqing
- Published
- 2021
- Full Text
- View/download PDF
7. A pH-responsive bioassay for sensitive colorimetric detection of adenosine triphosphate based on switchable DNA aptamer and metal ion–urease interactions.
- Author
-
Zhu, Sha, Yang, Yiqi, Li, Menglu, Yang, Yi, Li, Chao, and Yin, Yongmei
- Subjects
SINGLE-stranded DNA ,ADENOSINE triphosphate ,DNA structure ,APTAMERS ,DNA ,DNA probes ,CYTOSINE - Abstract
A facile and economic colorimetric strategy was designed for ATP detection by rationally using urease, a pH-responsive molecule, and a metal-mediated switchable DNA probe. By utilizing metal ions as a modulator of urease activity, the concentration of ATP is translated into pH change, which can be readily visualized by naked eye. An unmodified single-stranded DNA probe was designed, which consists of a target binding sequence and two flanked cytosine (C)-rich sequences. This C-rich single-stranded DNA can form a hairpin structure triggered by Ag
+ ions via C-Ag+ -C base mismatch. Upon introduction of ATP, Ag+ -coordinated hairpin DNA structure will be broken and release the included Ag+ , thus inhibiting the activity of urease. Conversely, urease can hydrolyze urea and raise pH value of the solution, resulting in the color change of the sensing solution. The proposed assay allows determination of ATP as low as 1.6 nM and shows a satisfactory result in human serum. Because of simple operation and low cost of this method, we believe it has a potential in point-of-care (POC) testing in resource-limited areas. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
8. Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study.
- Author
-
Xu, Binghe, Li, Wei, Zhang, Qingyuan, Shao, Zhimin, Li, Qiao, Wang, Xiaojia, Li, Huiping, Sun, Tao, Yin, Yongmei, Zheng, Hong, Feng, Jifeng, Zhang, Hong, Lei, Guiyuan, and Restuccia, Eleonora
- Abstract
Purpose: The Chinese bridging study PUFFIN (NCT02896855) aimed to assess consistency of efficacy with CLEOPATRA (NCT00567190), investigating pertuzumab with trastuzumab and docetaxel versus placebo, trastuzumab, and docetaxel in patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer. Methods: Patients were randomized 1:1, stratified by visceral/non-visceral disease and hormone receptor status. The primary endpoint was investigator-assessed progression-free survival (PFS). Secondary endpoints included objective response rate (in patients with measurable baseline disease), overall survival, and safety. The consistency threshold for PFS (hazard ratio [HR] < 0.81) (maintaining ≥ 50% of the risk reduction determined in CLEOPATRA [HR 0.62]) determined the target sample size (n = 240). Results: Two hundred forty-three patients were randomized. Median PFS was 14.5 months in the pertuzumab arm (95% confidence interval [CI] 12.5, 18.6) and 12.4 months in the placebo arm (95% CI 10.4, 12.7) in the intention-to-treat population (HR: 0.69 [95% CI 0.49, 0.99]). Objective responses were recorded in 83/105 (79.0%) and 67/97 (69.1%) patients, respectively. Grade ≥ 3 adverse events (70.5% and 69.2%, respectively) and serious adverse events (19.7% and 19.2%, respectively) were similar across both arms. No heart failure cases or symptomatic left ventricular ejection fraction declines were reported. Conclusions: PUFFIN met its primary objective. Overall, efficacy data were consistent with CLEOPATRA. Safety was consistent with the known pertuzumab safety profile. PUFFIN adds to the totality of data with pertuzumab in previously untreated HER2-positive locally recurrent or metastatic breast cancer and supports the favorable benefit–risk profile of pertuzumab in Chinese patients Trial registration: ClinicalTrials.gov, NCT02896855, registered 7 September 2016 [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
9. Establishment of Enhanced Chemiluminescent Immunoassay Formats for Stanozolol Detection in animal-derived foodstuffs and Other Matrices.
- Author
-
Wang, Jing, Zheng, Lei, Dong, Yaqing, Song, Zhaorui, Wang, Yufen, Meng, Meng, Ren, Linlin, Eremin, Sergei, Deng, Chuan, Yin, Yongmei, and Xi, Rimo
- Abstract
Stanozolol is one of the most widely used synthetic anabolic steroids but also presents a host of negative side effects. It is necessary to develop a rapid and sensitive method for stanozolol screening to monitor its abuse. In this study, the polyclonal antibody against stanozolol was prepared and a novel indirect competitive chemiluminescence enzyme immunoassay (CLEIA) for stanozolol was developed. The stanozolol hapten was conjugated to proteins to prepare immunogen and coating antigens, firstly. To improve the performances of the method, the chemiluminescent detection system was optimized. The optimal concentration of 4-iodophenol, hydrogen peroxide and luminol was studied and the proper detection time was also investigated. Under the optimal conditions, the IC value and the limit of detection (IC) of the chemiluminescence immunoassay is 0.34 and 0.07 ng/mL in phosphate-buffered saline (PBS), respectively. The accuracy performances of the proposed CLEIA were compared with that of ELISA and HPLC. Different nutraceuticals, foodstuffs, and biological matrices spiked with stanozolol were applied to study the application of the proposed assays, and the average recoveries locate at 92-113 % with the coefficients of variation of 8-13.5 %. The polyclonal antibody-based chemiluminescence immunoassay formats are proved to be a feasible and reliable quantificational method for stanozolol. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
10. ObRb downregulation increases breast cancer cell sensitivity to tamoxifen.
- Author
-
Qian, Yingying, Shi, Dongmin, Qiu, Jinrong, Zhu, Fang, Qian, Jing, He, Shaohua, Shu, Yongqian, Yin, Yongmei, and Chen, Xiaofeng
- Abstract
Leptin is a potent adipokine that plays an important role in the progression of breast cancer and interferes with the action of tamoxifen. We investigated the molecular mechanism underlying the effect of leptin on tamoxifen resistance in breast cancer cells that express leptin receptor (ObRb), and evaluated the impact of ObRb suppression on tamoxifen treatment in MCF-7 and tamoxifen-resistant (TAM-R) cells. Leptin-induced signaling pathway activation was examined by qRT-PCR and Western blotting. Chromatin immunoprecipitation assays were performed to further examine the binding of estrogen receptor (ER) α on the promoter of cyclin D1 ( CCND1) gene. The effects of combined ObRb knockdown and tamoxifen treatment were evaluated in MCF-7 and TAM-R cells. We found that the enhanced proliferation effects induced by leptin were related to extracellular-signal-regulated kinase (ERK) 1/2 and signal transducers and activators of transcription (STAT) 3 signaling pathway activation and CCND1 upregulation. Leptin enhanced CCND1 gene transcription by inducing the binding of ERα to the promoter of CCND1 gene. ObRb knockdown significantly enhanced the inhibitory effects of tamoxifen on TAM-R cell proliferation and survival. This study suggested that long-term endocrine therapy facilitates leptin and ObRb overexpression in breast cancer cells, which attenuates the inhibitory effect of tamoxifen by activating both the ERK1/2 and STAT3 signaling pathways and upregulating CCND1 gene expression. Combination therapy involving ObRb knockdown and tamoxifen treatment may be an alternative therapeutic option for tamoxifen-resistant breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
11. A sensitive chemiluminescent immunoassay for point-of-care testing of repaglinide in natural dietary supplements and serum.
- Author
-
Zheng, Lei, Wang, Jing, Wang, Yufen, Song, Zhaorui, Dong, Yaqing, Yin, Yongmei, Eremin, Sergei, Meng, Meng, and Xi, Rimo
- Subjects
DIETARY supplements ,CHEMICAL derivatives ,BENZOIC acid ,CHEMILUMINESCENCE assay ,IMMUNOASSAY ,SERUM ,HORSERADISH peroxidase - Abstract
For point-of-care testing of the illegal fortification of repaglinide (Rep) in natural dietary supplements, a competitive chemiluminescent immunoassay (CLIA) was established, using a horseradish peroxidase (HRP)-luminol-HO system for signal amplification. Polyclonal antibodies for Rep were produced via immunization technique. Following optimization of the enzyme reaction time and concentrations of antibody and coating antigen, the method showed a limit of quantification (LOQ) of 1.0 ng/mL in PBS and limit of detection (LOD) of 8.3 ng/mL in serum and 6.0 ng/mL in blank tablets. When applied in natural dietary supplements, the method provided results consistent with those from HPLC, suggesting that the proposed method could be used for rapid screening of Rep in natural dietary supplements and detecting Rep in serum after administration. [Figure not available: see fulltext.] [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
12. A Direct Enzyme Immunoassay to Detect Erythrosine in Foods.
- Author
-
Zhang, Bo, Du, Daolin, Yin, Yongmei, Zheng, Lei, Zhao, Junhong, Eremin, Sergei, Rybakov, Victor, Meng, Meng, and Xi, Rimo
- Abstract
As a synthetic food dye, erythrosine is associated with serious toxicity in inducing thyroid tumors, and the use of erythrosine is strictly regulated in most counties including China. In this study, a direct enzyme-linked immunosorbent assay (ELISA) has been developed for analysis of erythrosine in food products. A highly specific monoclonal antibody (MAb) for erythrosine was produced using erythrosine-bovine serum albumin (BSA) conjugate as an artificial antigen, and horseradish peroxidase (HRP)-labeled MAb for erythrosine was utilized as the detection antibody. Under the optimized condition, the UV absorbance in microplate related well with erythrosine concentration in the range of 0.1-10.0 μg/g. The proposed method could be applied to determine erythrosine in beverage and cookie, with good recoveries (80 -103 %) for the three spiked levels (30, 50, and 100 μg/g), and the relative standard deviations of detected amount were <12.3 %. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
13. Determination of Amaranth in Beverage by Indirect Competitive Enzyme-linked Immunosorbent Assay (ELISA) Based on Anti-amaranth Monoclonal Antibody.
- Author
-
Zhang, Bo, Du, Daolin, Meng, Meng, Eremin, Sergei, Rybakov, Victor, Zhao, Junhong, Yin, Yongmei, and Xi, Rimo
- Abstract
Amaranth (E 123) is a member of azo dyes, and it is allowed to use in various foods. The acceptable maximum addition of amaranth is strictly fixed because of its potential risk to physical health. The objective of this study was to prepare a specific anti-amaranth monoclonal antibody and develop an indirect competitive ELISA for amaranth quantification analysis. The immunogen and the coating antigen were designed by introducing a carboxyl group into amaranth for the conjugation with carrier proteins. Based on the immunogen, the monoclonal antibody exhibits satisfactory performances and the proposed ELISA shows an IC of 20.33 ng mL. The limit of detection is as low as 3.35 ng mL, and the linear standard curve of the method ranges from 3.0 to 243.0 ng mL. Additionally, the antibody reflects minimal cross-reactivity (<1 %) with six related food dyes (erythrosine, ponceau 4R, allura red, tartrazine, sunset yellow FCF, and brilliant blue). The recoveries of amaranth spiked beverage samples are in the range of 85.8-100.7 % with low coefficient of variation values (<11.5 %). The data shows that the developed ELISA provides a simple, sensitive, specific, and accurate alternative for amaranth determination and monitoring. Furthermore, it is the first time that icELISA of amaranth is developed based on monoclonal antibodies. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
14. Electrochemical method to characterize multidrug resistance.
- Author
-
Lu, Shan, Ning, Limin, Gao, Tao, Wu, Xiaolan, Yin, Yongmei, and Li, Genxi
- Published
- 2014
- Full Text
- View/download PDF
15. Human epidermal growth factor receptor-2 expression in primary and metastatic gastric cancer.
- Author
-
Geng, Yiting, Chen, Xiaofeng, Qiu, Jinrong, Zhou, Yue, Wang, Jian, Liu, Lingxiang, Shao, Yongfeng, and Yin, Yongmei
- Subjects
EPIDERMAL growth factor receptors regulation ,GENE expression ,STOMACH cancer treatment ,GENE amplification ,STOMACH cancer ,NEOVASCULARIZATION ,IMMUNOHISTOCHEMISTRY ,PROGNOSIS - Abstract
Background: Amplification and overexpression of human epidermal growth factor receptor-2 (HER-2) has been shown in subgroups of gastric cancer, correlated to more aggressive disease and predictive for the treatment with HER-2 antibodies. In this study, we examined the prognostic value of HER-2 expression in primary gastric cancer and in associated lymph node metastases and confirmed the role of HER-2 in tumor angiogenesis by examining vascular endothelial growth factor (VEGF) expression. Methods: Immunohistochemistry was used to detect HER-2 and VEGF expression in 110 gastric cancer specimens and associated lymph node metastases and in 96 specimens of normal gastric mucosa. Results: The expression level of HER-2 in gastric tissues was significantly higher than in normal tissues (19.1 % vs. 8.3 %; P < 0.05). HER-2 overexpression was homogeneous in primary gastric cancer and metastatic lymph nodes ( P = 0.607). There was a significant positive correlation of HER-2 expression and VEGF expression ( P = 0.007). HER-2 overexpression in primary tumor correlated with lymph node metastasis, distant metastasis, and American Joint Committee on Cancer (AJCC) stage. Cox regression multivariate analyses confirmed that tumor size, histological grade, lymph node ratio, AJCC stage, chemotherapy, and HER-2 expression were all prognostic factors. Patients with HER-2 positivity in both primary and metastatic tissues (+/+) had the poorest survival (OS, 12.5 months; DFS, 11.0 months) ( P < 0.01). Conclusions: HER-2 was significantly overexpressed in gastric cancer versus normal tissue and correlated with VEGF expression. HER-2 in tumor or lymph nodes was an independent negative prognostic factor. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
16. Electrochemical assay of the relationship between the inhibition of phosphatidylinositol 3-kinase pathway and estrogen receptor expression in breast cancer.
- Author
-
Zhu, Sha, Cao, Ya, Ye, Zonghuang, Yin, Yongmei, and Zhu, Xiaoli
- Subjects
ESTROGEN receptors ,BREAST cancer research ,PHOSPHATIDYLINOSITOL 3-kinases ,CANCER cells ,ELECTROCHEMICAL research - Abstract
Breast cancer has become one of the most threatening diseases to women throughout the world. Emerging evidence implies that estrogen receptor (ER) and phosphatidylinositol 3-kinase (PI3K) pathways play central roles in both breast cancer progression and response to therapy. In this work, we have probed into ER expression related to the PI3K pathway at the protein level with an electrochemical technique based on the detection of ER proteins in nuclear extracts with an Exonuclease III protection-based strategy. Experimental results show that an increased number of ER proteins can be detected upon PI3K inhibition, demonstrating the reversal effect of the PI3K inhibitor on ER expression. Moreover, treatment with different concentrations of the PI3K inhibitor NVP-BEZ235 can result in a dose-dependent alteration of ER protein levels, implying an intimate link between ER and PI3K pathways. This work may be a great help to understand the mysteries underlying PI3K-related endocrine resistance and to evaluate the effect of therapeutic interventions in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
17. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer.
- Author
-
Zhao, Wan, Hu, Lingmin, Xu, Jiali, Shen, Hongbing, Hu, Zhibin, Ma, Hongxia, Shu, Yongqian, Shao, Yongfeng, and Yin, Yongmei
- Subjects
GENETIC polymorphisms ,LUNG cancer treatment ,PHYSIOLOGICAL effects of platinum ,CANCER chemotherapy ,SINGLE nucleotide polymorphisms ,CANCER prognosis - Abstract
Purpose: Platinum-based chemotherapy is the most common treatment for patients with advanced non-small cell lung cancer (NSCLC). Genetic polymorphisms in the base excision repair (BER) pathway are suspected to influence the response of patients to this type of therapy. In this study, we investigated whether nonsynonymous single nucleotide polymorphisms (SNPs) in the BER pathway were associated with the response, progression-free survival (PFS) and overall survival (OS) of NSCLC patients following platinum-based chemotherapy. Methods: We used TaqMan to genotype four SNPs ( APE1 Asp148Glu, PARP1 Va1762Ala, XRCC1 Arg194Trp and XRCC1 Arg399Gln) in 147 patients with advanced NSCLC who had undergone routine platinum-based chemotherapy. Results: Logistic regression analysis showed that subjects with the XRCC1-399 A allele had a significantly better response to platinum-based chemotherapy than those with the XRCC1-399 GG genotype (AA/AG vs. GG: adjusted OR = 2.35, 95 % CI = 1.11-5.00). Furthermore, multivariate Cox proportional hazard regression analysis showed that the PARP1-762 CC genotype was a significantly unfavorable prognostic factor for PFS (CC vs. CT/TT: adjusted HR = 1.90, 95 % CI = 1.02-3.52). In contrast, the APE1-148 GG genotype was a significantly protective prognostic factor for OS (GG vs. TT: adjusted HR = 0.33, 95 % CI = 0.12-0.92). Conclusions: We found that XRCC1 Arg399Gln, PARP1 Va1762Ala and APE1 Asp148Glu SNPs in the BER pathway may influence the prognosis of advanced NSCLC patients following platinum-based chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
18. A case of intimal sarcoma of the pulmonary artery successfully treated with chemotherapy.
- Author
-
Xu, Yanjie, Wang, Kai, Geng, Yiting, Shao, Yongfeng, and Yin, Yongmei
- Subjects
PULMONARY artery diseases ,CANCER treatment ,SARCOMA ,CANCER chemotherapy ,TREATMENT effectiveness ,DISEASES in middle-aged women ,ENDARTERECTOMY ,CANCER tomography ,THERAPEUTICS - Abstract
Intimal sarcoma of pulmonary artery (PAIS) is a rare disease with no characteristic symptoms. No standard therapeutic guidelines have been established so far. A 55-year-old woman who underwent pulmonary endarterectomy in 2005 with a pathological and immunohistochemical result of PAIS was re-admitted to our hospital on August 24, 2009, presenting with cough and dyspnea. The thoracic computed tomography (CT) scan revealed a 12.5 cm × 9 cm well-defined mass in the right lobe, considered a local neoplasm recurrence after a 44 month symptom-free period. As surgical resection was not proposed, she received combined chemotherapy consisting of doxorubicin, cisplatin, and ifosfamide for two cycles. Because of intolerable side effects, she received vinorelbine and cisplatin for the next four cycles. CT scans after six cycles showed remarkable regression of the tumor. After that, she began to take oral cyclophosphamide (50 mg t.i.d) everyday as a maintenance therapy. As of the time of writing, 19 months after the onset of the recurrence, she remains stable. Several antineoplastic drugs have been reported to be used in PAIS, with poor effects in most cases. To our knowledge, this is the first case of PAIS that has been successfully treated by a vinorelbine-based regimen used as second-line chemotherapy. Vinorelbine is a promising drug that may be relatively well tolerated in heavily pretreated patients with PAIS. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
19. Comparative SPR study on the effect of nanomaterials on the biological activity of adsorbed proteins.
- Author
-
Mei, Qiaohan, Ding, Xiaorong, Chen, Yangyang, Hong, Jiang, Koh, Kwangnak, Lee, Jaebeom, Chen, Hongxia, and Yin, Yongmei
- Subjects
COMPARATIVE studies ,NANOSTRUCTURED materials ,PROTEIN analysis ,BIOACTIVE compounds ,SURFACE plasmon resonance ,CARBON nanotubes - Abstract
Bioactivity of proteins is evaluated to test the adverse effects of nanoparticles interjected into biological systems. Surface plasmon resonance (SPR) spectroscopy detects binding affinity that is normally related to biological activity. Utilizing SPR spectroscopy, a concise testing matrix is established by investigating the adsorption level of bovine serum albumin (BSA) and anti-BSA on the surface covered with 11-mercaptoundecanoic acid (MUA); magnetic nanoparticles (MNPs) and single-walled carbon nanotubes (SWCNTs), respectively. The immunoactivity of BSA on MNPs and SWCNT decreased by 18 % and 5 %, respectively, compared to that on the gold film modified with MUA. This indicates that MNPs cause a considerable loss of biological activity of adsorbed protein. This effect can be utilized for practical applications on detailed biophysical research and nanotoxicity studies. [Figure not available: see fulltext.] [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
20. Association between survivin −31G>C promoter polymorphism and cancer risk: a meta-analysis.
- Author
-
Wang, Xiefeng, Huang, Lili, Xu, Yanjie, Shi, Zhumei, Wang, Yingyi, Zhang, Junxia, Wang, Xirui, Cao, Lei, Luo, Hui, Chen, Jiawei, Liu, Ning, Yin, Yongmei, and You, Yongping
- Subjects
SURVIVIN (Protein) ,GENETIC polymorphisms ,CANCER risk factors ,META-analysis ,DISEASE susceptibility - Abstract
Survivin is an inhibitor of apoptosis protein and has a crucial role in the development of cancer. The survivin −31G>C (rs9904341) promoter polymorphism influences survivin expression and has been implicated in cancer risk. However, conflicting results have been published from studies on the association between survivin −31G>C polymorphism and the risk of cancer. To clarify the role of this polymorphism in cancer, we performed a meta-analysis of all available and relevant published studies, involving a total of 3485 cancer patients and 3964 control subjects. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the strength of the associations. The overall results indicated that the variant genotypes were associated with a significantly increased cancer risk (CC vs GG: OR=1.58, 95% CI=1.20-2.10; CC/GC vs GG: OR=1.23, 95% CI=1.00-1.51; CC vs GG/GC: OR=1.51, 95% CI=1.23-1.85). In the stratified analyses, significantly increased risk was associated with the Asian populations (CC vs GG: OR=1.67, 95% CI=1.16-2.40; CC vs GG/GC: OR=1.50, 95% CI=1.17-1.91). We also performed the analyses by cancer type, and no statistical association was observed. The results suggest that the survivin −31G>C promoter polymorphism might be associated with an increased risk of cancer, especially in the Asian populations. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
21. The effects of cytokine-induced killer cells for the treatment of patients with solid tumors: a clinical retrospective study.
- Author
-
Zhang, Jinying, Zhu, Lingjun, Wei, Juan, Liu, Lingxiang, Yin, Yongmei, Gu, Yanhong, and Shu, Yongqian
- Subjects
CYTOKINES ,KILLER cells ,RETROSPECTIVE studies ,IMMUNOTHERAPY ,INTERFERONS ,CANCER ,INTERLEUKIN-2 - Abstract
Background: Cytokine-induced killer (CIK) cells exert high impact on adoptive immunotherapeutic approaches for malignant tumors. This study aimed to evaluate the effect of adjuvant immunotherapy with CIK cells on the prognosis of solid tumor. Methods: Peripheral blood mononuclear cells were collected by a blood cell separator from 40 patients, then expanded by priming them with interferon-gamma followed by monoclonal antibody against CD3 and interleukin-2 the next day. The phenotypic patterns of CIK cells were characterized by flow cytometry on days 0, 7, 10, 14 and 21 of incubation, respectively. Then, 5 ml of venous blood was obtained from 40 patients before and after CIK cells were transfused into patients to assess the influence of CIK cells on the percentages of effector cells. Results: After 14 days of incubation in vitro, the percentages of CD3, CD8, CD3 and CD56 increased significantly ( P < 0.05). The clinical symptoms of 40 patients were improved apparently. The 6-month, 1-year and 3-year overall survival rates were 70.0, 60.0 and 57.5%, respectively. Conclusions: Our results indicated that CIKs immunotherapy can be an effective adjuvant instrument of the routine therapy of malignancy. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
22. Comparative study of gemcitabine plus cisplatin and gemcitabine plus fluorouracil in the treatment of advanced pancreatic cancer.
- Author
-
Shu, Yongqian, Liu, Lianke, Liu, Lingxiang, Huang, Puwen, Lu, Kaihua, and Yin, Yongmei
- Abstract
To compare the efficacy and toxicity of gemcitabine plus cisplatin and gemcitabine plus fluorouracil in the treatment of advanced pancreatic cancer. Sixty patients with advanced pancreatic cancer were randomly divided into a GP group (gemcitabine + cisplatin, 30 cases) and a GF group (gemcitabine + fluorouracil, 30 cases). All patients were treated with gemcitabine at a dose of 1,000mg/m
2 (diluted in 100ml saline solution over 30 min) once a week for 3 consecutive weeks. The GP Group was followed by 40mg cisplatin via intravenous drip on days 15,16,17. Group GF was followed by 500mg/m2 5-Fu (diluted in 5% glucose-saline (GS) 500ml, intravenously, over 6 hr) every day for five subsequent days. In the GP group, eight cases (32.0%) were PR and MR, the median survival time was 8.7 months, the Clinical Beneficial Rate (CBR) was 57.7%, and the CA19-9 decreased by over 50% in 13 cases (48.1%). In the GF group, 11 cases (45.8%) were PR and MR, the survival time was 10.1 months, the CBR was 82.1%, and CA19-9 decreased by over 50% in 15 cases(53.6%). There was a significant difference in the CBR between the two groups (P<0.05). The main toxicities in both groups were leucopenia and thrombocytopenia with no significant difference. The treatment given to either the GP or GF group is a feasible and well-tolerated chemotherapy regimen for treating advanced pancreatic cancer with improved therapeutic efficacy and few side effects. The median survival period is long and the CBR is high, especially with the GF regimen. [ABSTRACT FROM AUTHOR]- Published
- 2004
- Full Text
- View/download PDF
23. A colorimetric ATP assay based on the use of a magnesium(II)-dependent DNAzyme.
- Author
-
Zhu, Sha, Wang, Xiaoying, Jing, Cheng, Yin, Yongmei, and Zhou, Nandi
- Subjects
DNA probes ,GOLD nanoparticles ,APTAMERS ,NUCLEOTIDE sequence ,MAGNESIUM ,ADENOSINE triphosphate - Abstract
A colorimetric assay for ATP is described that uses a strategy that combines the concept of split Mg(II)-dependent DNAzyme, split aptamer, and hybridization-induced aggregation of gold nanoparticles (AuNPs). Both ATP aptamer and Mg(II)-dependent DNAzyme are split into two fragments which are allocated to two well-designed DNA probes. The probes also possess mutually complementary stem sequences and spacer sequences. In the presence of ATP, the separated DNAzyme sequences in the two probes assemble via the synchronous recognition of ATP with two fragments of the aptamer. Then, the activated DNAzyme catalyzes multiple cycles of the cleavage of its substrate DNA sequence. The latter acts as a linker and induces the aggregation of two types of ssDNA-modified AuNP through the hybridization between the complementary sequences. Thus, the color of the AuNP solution remains red. However, in the absence of ATP, the detached aptamer cannot induce the assembly of DNAzyme to cleave the linker DNA. This results in the aggregation of AuNP and a concomitant color transition from red to purple. This ATP assay, performed at a wavelength of 530 nm, has a linear detection range that extends from 10 pM to 100 nM, with a detection limit of 5.3 pM. It was applied to the detection of ATP in human serum. Conceivably, the strategy has a wide scope in that it may be applied to the colorimetric detection of various other analytes through the split aptamer configuration.Schematic presentation of colorimetric assay for adenosine triphosphate (ATP) based on the use of a split Mg(II)-dependent DNAzyme, a split aptamer, and by exploiting the hybridization-induced aggregation of gold nanoparticles that leads to a color change from red to purple [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
24. BRCA1 inhibits AR-mediated proliferation of breast cancer cells through the activation of SIRT1.
- Author
-
Zhang, Wenwen, Luo, Jiayan, Yang, Fang, Wang, Yucai, Yin, Yongmei, Strom, Anders, Gustafsson, Jan Åke, and Guan, Xiaoxiang
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.